IMMULITE 2000 Hepatitis B Surface Antigen (HBsAg), IMMULITE 2000 Hepatitis B Surface Antigen (HBsAg) Confirmatory Kit
Siemens Healthcare Diagnostics Products, Ltd. · Decision date Sep 18, 2025
What did the FDA approve?
FDA records P010050/S026 as a supplement to PMA P010050, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Sep 18, 2025.
FDA approval order statement
to relocate processes for critical raw materials to a site previously approved in the submission
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Sep 18, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P010050/S026
- Regulatory pathway
- PMA supplement
- Product code
- LOM
- Decision code
- APPR
- Decision date
- Sep 18, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen).
- Product code
- LOM
- FDA device class
- 2
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P010050/S026 received
Application receipt date recorded by FDA.
P010050/S025 · Related supplement
IMMULITE 2000 Hepatitis B Surface Antigen (HBsAg), IMMULITE 2000 Hepatitis B Surface Antigen (HBsAg) Confirmatory Kit
P010050/S026 · FDA decision
135 Review Track For 30-Day Notice
Timeline entries are records held by MedtechLedger for P010050. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010050
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Siemens Healthcare Diagnostics Products, Ltd. | PMA supplement | Sep 18, 2025 | FDA |
Explore the linked device profile
Other records with product code LOM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| DiaSorin, Inc. | 510(k) clearance | Jun 4, 2026 | FDA | |
Atellica IM Hepatitis B core IgM (aHBcM)P030040/S024 | Siemens Healthcare Diagnostics | PMA supplement | Oct 17, 2025 | FDA |
Atellica IM Hepatitis B e Antigen (HBeAg)P090024/S013 | Siemens Healthcare Diagnostics | PMA supplement | Oct 17, 2025 | FDA |
| Siemens Healthcare Diagnostics, Inc. | PMA supplement | Oct 17, 2025 | FDA | |
| Siemens Corp. | PMA supplement | Oct 17, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Siemens Healthcare Diagnostics Products, Ltd.
- Headquarters
- Not reported
- Brand website
- siemens-healthineers.com
- FDA applicant address
- Glyn Rhonwy, Llanberis, LL55 4EL
Sources and methodology
- Original FDA record: P010050/S026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


